Monday, January 8, 2018
Home »
business news
» Novo Nordisk's $3.1B Ablynx bid rejected by Belgian biotech
Novo Nordisk's $3.1B Ablynx bid rejected by Belgian biotech
Novo Nordisk's $3.1B Ablynx bid rejected by Belgian biotech
Denmark's Novo Nordisk, the world's biggest maker of insulin, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday as it seeks to bolster its treatments for rare blood disorders.
Interest rates held at 5% but 'on the path down'
Economists are betting on rates being held in September with a cut to come in November instead. from BBC News https://ift.tt/OyPldkf
0 comments:
Post a Comment